<!DOCTYPE html>
<html lang="en"><head>
  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <title>Personalized Predictions from Population Level Experiments: A Study on Alzheimer's Disease</title><!-- Begin Jekyll SEO tag v2.7.1 -->
<meta name="generator" content="Jekyll v3.9.5" />
<meta property="og:title" content="Personalized Predictions from Population Level Experiments: A Study on Alzheimer’s Disease" />
<meta name="author" content="Dennis Shen, Anish Agarwal, Vishal Misra, Bjoern Schelter, Devavrat Shah, Helen Shiells, Claude Wischik" />
<meta property="og:locale" content="en_US" />
<meta name="description" content="The purpose of this article is to infer patient level outcomes from population level randomized control trials (RCTs). In this pursuit, we utilize the recently proposed synthetic nearest neighbors (SNN) estimator. At its core, SNN leverages information across patients to impute missing data associated with each patient of interest. We focus on two types of missing data: (i) unrecorded outcomes from discontinuing the assigned treatments and (ii) unobserved outcomes associated with unassigned treatments. Data imputation in the former powers and de-biases RCTs, while data imputation in the latter simulates “synthetic RCTs” to predict the outcomes for each patient under every treatment. The SNN estimator is interpretable, transparent, and causally justified under a broad class of missing data scenarios. Relative to several standard methods, we empirically find that SNN performs well for the above two applications using Phase 3 clinical trial data on patients with Alzheimer’s Disease. Our findings directly suggest that SNN can tackle a current pain point within the clinical trial workflow on patient dropouts and serve as a new tool towards the development of precision medicine. Building on our insights, we discuss how SNN can further generalize to real-world applications." />
<meta property="og:description" content="The purpose of this article is to infer patient level outcomes from population level randomized control trials (RCTs). In this pursuit, we utilize the recently proposed synthetic nearest neighbors (SNN) estimator. At its core, SNN leverages information across patients to impute missing data associated with each patient of interest. We focus on two types of missing data: (i) unrecorded outcomes from discontinuing the assigned treatments and (ii) unobserved outcomes associated with unassigned treatments. Data imputation in the former powers and de-biases RCTs, while data imputation in the latter simulates “synthetic RCTs” to predict the outcomes for each patient under every treatment. The SNN estimator is interpretable, transparent, and causally justified under a broad class of missing data scenarios. Relative to several standard methods, we empirically find that SNN performs well for the above two applications using Phase 3 clinical trial data on patients with Alzheimer’s Disease. Our findings directly suggest that SNN can tackle a current pain point within the clinical trial workflow on patient dropouts and serve as a new tool towards the development of precision medicine. Building on our insights, we discuss how SNN can further generalize to real-world applications." />
<link rel="canonical" href="https://emanuelealiverti.github.io/arxiv_rss/2024/05/31/PersonalizedPredictionsfromPopulationLevelExperimentsAStudyonAlzheimersDisease.html" />
<meta property="og:url" content="https://emanuelealiverti.github.io/arxiv_rss/2024/05/31/PersonalizedPredictionsfromPopulationLevelExperimentsAStudyonAlzheimersDisease.html" />
<meta property="og:site_name" content="Stat Arxiv of Today" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2024-05-31T00:00:00+00:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="Personalized Predictions from Population Level Experiments: A Study on Alzheimer’s Disease" />
<script type="application/ld+json">
{"description":"The purpose of this article is to infer patient level outcomes from population level randomized control trials (RCTs). In this pursuit, we utilize the recently proposed synthetic nearest neighbors (SNN) estimator. At its core, SNN leverages information across patients to impute missing data associated with each patient of interest. We focus on two types of missing data: (i) unrecorded outcomes from discontinuing the assigned treatments and (ii) unobserved outcomes associated with unassigned treatments. Data imputation in the former powers and de-biases RCTs, while data imputation in the latter simulates “synthetic RCTs” to predict the outcomes for each patient under every treatment. The SNN estimator is interpretable, transparent, and causally justified under a broad class of missing data scenarios. Relative to several standard methods, we empirically find that SNN performs well for the above two applications using Phase 3 clinical trial data on patients with Alzheimer’s Disease. Our findings directly suggest that SNN can tackle a current pain point within the clinical trial workflow on patient dropouts and serve as a new tool towards the development of precision medicine. Building on our insights, we discuss how SNN can further generalize to real-world applications.","author":{"@type":"Person","name":"Dennis Shen, Anish Agarwal, Vishal Misra, Bjoern Schelter, Devavrat Shah, Helen Shiells, Claude Wischik"},"datePublished":"2024-05-31T00:00:00+00:00","mainEntityOfPage":{"@type":"WebPage","@id":"https://emanuelealiverti.github.io/arxiv_rss/2024/05/31/PersonalizedPredictionsfromPopulationLevelExperimentsAStudyonAlzheimersDisease.html"},"url":"https://emanuelealiverti.github.io/arxiv_rss/2024/05/31/PersonalizedPredictionsfromPopulationLevelExperimentsAStudyonAlzheimersDisease.html","headline":"Personalized Predictions from Population Level Experiments: A Study on Alzheimer’s Disease","@type":"BlogPosting","dateModified":"2024-05-31T00:00:00+00:00","@context":"https://schema.org"}</script>
<!-- End Jekyll SEO tag -->
<link type="application/atom+xml" rel="alternate" href="https://emanuelealiverti.github.io/arxiv_rss/feed.xml" title="Stat Arxiv of Today" /><link rel="shortcut icon" type="image/x-icon" href="" />
  <link rel="stylesheet" href="/arxiv_rss/assets/css/main.css" />


<script>
MathJax = {
  tex: {
    inlineMath: [['$', '$'], ['\\(', '\\)']]
  },
  svg: {
    fontCache: 'global'
  }
};
</script>
<script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>


</head>
<body a="light">
    <main class="page-content" aria-label="Content">
      <div class="w">
        <a href="/arxiv_rss/">..</a><article>
  <p class="post-meta">
    <time datetime="2024-05-31 00:00:00 +0000">05-31</time>
  </p>
  
  <h1>Personalized Predictions from Population Level Experiments: A Study on Alzheimer's Disease</h1>
  <br>Dennis Shen, Anish Agarwal, Vishal Misra, Bjoern Schelter, Devavrat Shah, Helen Shiells, Claude Wischik</h3>
  <br> [stat.AP,stat.ME]

  <p>The purpose of this article is to infer patient level outcomes from population level randomized control trials (RCTs). In this pursuit, we utilize the recently proposed synthetic nearest neighbors (SNN) estimator. At its core, SNN leverages information across patients to impute missing data associated with each patient of interest. We focus on two types of missing data: (i) unrecorded outcomes from discontinuing the assigned treatments and (ii) unobserved outcomes associated with unassigned treatments. Data imputation in the former powers and de-biases RCTs, while data imputation in the latter simulates “synthetic RCTs” to predict the outcomes for each patient under every treatment. The SNN estimator is interpretable, transparent, and causally justified under a broad class of missing data scenarios. Relative to several standard methods, we empirically find that SNN performs well for the above two applications using Phase 3 clinical trial data on patients with Alzheimer’s Disease. Our findings directly suggest that SNN can tackle a current pain point within the clinical trial workflow on patient dropouts and serve as a new tool towards the development of precision medicine. Building on our insights, we discuss how SNN can further generalize to real-world applications.</p>

<p><a href="https://arxiv.org/abs/2405.20088">Read more</a></p>

</article>

      </div>
    </main>
  </body>
</html>